Cell Free DNA (cfDNA) Testing Global Market Report 2025
상품코드:1825656
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세포 유리 DNA(cfDNA) 검사 시장 규모는 향후 몇 년 동안 비약적인 성장이 예상됩니다. 2029년에는 CAGR 22.4%로 243억 4,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 개인 맞춤형 의료로의 전환, 헬스케어 인프라 강화, 고령화 및 암 발병률 증가, 정밀의료 도입 증가, 액체생검 기술에 대한 인식과 수용성 증가, cfDNA 연구에 대한 투자 및 자금 조달 증가에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 액체 생검 기술 채택, 차세대 염기서열 분석(NGS) 기술 발전, cfDNA 검사에 AI와 머신러닝의 통합, 포인트 오브 케어 cfDNA 검사 개발, 데이터 저장 및 분석을 위한 클라우드 기반 플랫폼 도입 등을 들 수 있습니다.
향후 5년간 22.4%의 성장률 전망은 지난번 예측보다 0.5% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 한국이나 스웨덴에서 수입되는 차세대 염기서열분석(NGS) 기반 무세포 cfDNA 키트와 디지털 중합효소 연쇄반응(PCR) 시스템의 비용을 상승시킴으로써 미국의 액체생검 도입에 혼란을 야기할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
암 유병률 증가는 향후 무세포 DNA(cfDNA) 검사 시장의 성장을 가속할 것으로 예측됩니다. 암은 체내에서 비정상적인 세포의 증식과 확산을 특징으로 하는 복잡한 질병군을 포괄합니다. 이 세포들은 정상 조직에 침입하여 손상을 입힐 수 있으며, 방치할 경우 심각한 위험을 초래할 수 있습니다. 암 발병률 증가는 인구의 고령화, 생활습관의 변화, 환경의 영향, 검출 및 진단 방법의 발전 등의 요인에 기인합니다. cfDNA 검사는 암과 관련된 유전자 변이를 종종 증상이 나타나기 전에 조기에 발견할 수 있습니다. 이러한 조기 발견을 통해 적시에 개입할 수 있으며, 암을 조기에 발견함으로써 환자의 예후와 생존율을 향상시킬 수 있습니다. 예를 들어, 2024년 2월 세계보건기구(WHO)는 2050년까지 새로 발생하는 암 환자 수가 3,500만 명을 넘어설 것으로 예측했는데, 이는 2022년 추정 환자 수 2,000만 명에서 77% 증가한 수치입니다. 따라서 암 유병률 증가는 무세포 DNA(cfDNA) 검사 시장의 성장을 가속하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 세포 유리 DNA(cfDNA) 검사 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 세포 유리 DNA(cfDNA) 검사 시장 : 성장률 분석
세계의 세포 유리 DNA(cfDNA) 검사 시장 실적 : 규모와 성장, 2019-2024
세계의 세포 유리 DNA(cfDNA) 검사 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 세포 유리 DNA(cfDNA) 검사 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 세포 유리 DNA(cfDNA) 검사 시장 : 제품별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
기증자 유래 유리 DNA
순환 유리 세포 종양 DNA
유리 태아 DNA
세계의 세포 유리 DNA(cfDNA) 검사 시장 플랫폼별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
차세대 시퀀싱(NGS)
rPCR 및 멀티플렉스 PCR
qPCR 및 dPCR
기타 플랫폼
세계의 세포 유리 DNA(cfDNA) 검사 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
종양학
비침습적 산전 검사(NIPT)
부인과
이식
기타 용도
세계의 세포 유리 DNA(cfDNA) 검사 시장 : 세분화 기증자 유래 유리 DNA(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
장기 이식 모니터링
이식편 거부반응 감지
세계의 세포 유리 DNA(cfDNA) 검사 시장 : 세분화 순환 유리 세포 종양 DNA(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
암 감지
미세잔존질환 모니터링
액체생검
세계의 세포 유리 DNA(cfDNA) 검사 시장 : 세분화 유리 태아 DNA(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
비침습적 산전 검사(NIPT)
태아 유전성 질환 스크리닝
제7장 지역별/국가별 분석
세계의 세포 유리 DNA(cfDNA) 검사 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 세포 유리 DNA(cfDNA) 검사 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
세포 유리 DNA(cfDNA) 검사 시장 : 경쟁 구도
세포 유리 DNA(cfDNA) 검사 시장 : 기업 개요
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Laboratory Corporation of America Holdings : 개요, 제품 및 서비스, 전략 및 재무 분석
Quest Diagnostics Incorporated : 개요, 제품 및 서비스, 전략 및 재무 분석
Agilent Technologies Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Illumina Inc.
Qiagen N.V.
Exact Sciences Corporation
Bio-Techne Corporation
Natera Inc.
Myriad Genetics Inc.
NeoGenomics Laboratories Inc.
Invitae Corporation
Foundation Medicine Inc.
Guardant Health Inc.
Integrated DNA Technologies Inc.
Caris Life Sciences Inc.
Twist Bioscience Corporation
Adaptive Biotechnologies Corporation
Biodesix Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
세포 유리 DNA(cfDNA) 검사 시장(2029년) : 새로운 기회를 제공하는 국가
세포 유리 DNA(cfDNA) 검사 시장(2029년) : 새로운 기회를 제공하는 부문
세포 유리 DNA(cfDNA) 검사 시장(2029년) : 성장 전략
시장 동향에 근거한 전략
경쟁 전략
제36장 부록
LSH
영문 목차
영문목차
Cell-free DNA (cfDNA) testing is a non-invasive diagnostic technique that examines DNA fragments freely circulating in the bloodstream. This testing method is integral to liquid biopsy procedures, enabling the detection and analysis of genetic mutations and alterations without resorting to traditional tissue biopsies.
The primary products within the cell-free DNA (cfDNA) testing market include donor-derived cell-free DNA, circulating cell-free tumor DNA, and cell-free fetal DNA. Donor-derived cell-free DNA originates from transplanted donor organs or tissues and can be found in the recipient's bloodstream. Various platforms are utilized for cfDNA testing, such as next-generation sequencing (NGS), real-time PCR (rPCR) and multiplex PCR, quantitative PCR (qPCR) and digital PCR (dPCR), among others. These platforms are applied across various domains including oncology, non-invasive prenatal testing (NIPT), gynecology, transplantation, and other medical conditions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The cell-free DNA (cfDNA) testing market research report is one of a series of new reports from The Business Research Company that provides cell-free DNA (cfDNA) testing market statistics, including cell-free DNA (cfDNA) testing industry global market size, regional shares, competitors with a cell-free DNA (cfDNA) testing market share, detailed cell-free DNA (cfDNA) testing market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-free DNA (cfDNA) testing industry. This cell-free DNA (cfDNA) testing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cell free dna (cfdna) testing market size has grown exponentially in recent years. It will grow from $8.74 billion in 2024 to $10.84 billion in 2025 at a compound annual growth rate (CAGR) of 24.0%. The growth in the historic period can be attributed to a rise in the adoption of cfDNA testing in prenatal care, increasing use of cfDNA analysis, growing interest in cfDNA research across various medical fields, and rise in gaining approvals from regulatory bodies.
The cell free dna (cfdna) testing market size is expected to see exponential growth in the next few years. It will grow to $24.34 billion in 2029 at a compound annual growth rate (CAGR) of 22.4%. The growth in the forecast period can be attributed to a shift towards personalized medicine, enhancements in healthcare infrastructure, aging population and increasing incidence of cancer, increasing adoption of precision medicine, increasing awareness and acceptance of liquid biopsy techniques, and increasing investment and funding in cfDNA research. Major trends in the forecast period include adoption of liquid biopsy technologies, advancements in Next-Generation Sequencing (NGS) technology, integration of AI and machine learning in cfDNA testing, development of point-of-care cfDNA tests, and implementation of cloud-based platforms for data storage and analysis.
The forecast of 22.4% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. liquid biopsy adoption by increasing costs for Next-Generation Sequencing(NGS)-based cell-free cfDNA kits and digital Polymerase Chain Reaction(PCR) systems imported from South Korea and Sweden, potentially delaying cancer detection and raising diagnostic costs by $200-500 per test. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of cancer is expected to drive the growth of the cell-free DNA (cfDNA) testing market in the future. Cancer encompasses a complex group of diseases characterized by abnormal cell growth and spread in the body. These cells can invade and damage normal tissue, posing significant risks if left unchecked. The rise in cancer prevalence is attributed to factors such as aging populations, lifestyle changes, environmental influences, and advancements in detection and diagnostic methods. cfDNA testing detects genetic mutations linked to cancer at early stages, often before symptoms manifest. This early detection enables timely interventions, enhancing patient outcomes and survival rates by identifying cancer in its initial phases. For example, in February 2024, the World Health Organization (WHO) projected over 35 million new cancer cases by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Hence, the increasing prevalence of cancer is fueling the growth of the cell-free DNA (cfDNA) testing market.
Key players in the cell-free DNA (cfDNA) testing market prioritize the development of innovative technologies, such as liquid biopsy tests that offer heightened sensitivity, specificity, and efficiency in detecting cancer-related mutations and genetic changes. Liquid biopsy tests involve diagnostic procedures enabling oncologists to assess circulating cell-free DNA released by tumor cells, facilitating personalized and targeted therapy strategies. For instance, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences company, introduced Labcorp Plasma Focus, a new liquid biopsy test tailored for patients with advanced or metastatic solid tumors. This test evaluates circulating cell-free DNA (cfDNA) from tumor cells through a standard blood draw, ensuring minimal invasiveness and rapid results. It enhances access to precision oncology by identifying clinically actionable biomarkers across various common cancers such as non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.
In February 2022, Laboratory Corporation of America Holdings (LabCorp), a US-based clinical healthcare company, acquired Personal Genome Diagnostics Inc. for an undisclosed sum. This acquisition positions LabCorp to advance its existing liquid biopsy capabilities and broaden its array of state-of-the-art next-generation sequencing (NGS)-based genomic profiling tools for cancer, positioning it at the forefront of improving patient outcomes. Personal Genome Diagnostics Inc. specializes in precision oncology diagnostics, including cell-free DNA testing technology.
Major companies operating in the cell free DNA (CFDNA) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC
North America was the largest region in the cell-free DNA (CFDNA) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (CFDNA)) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cell free DNA (CFDNA) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cell-free DNA (cfDNA) testing market consists of revenue entities earned by providing services such as liquid biopsy for cancer detection and monitoring, transplant rejection monitoring, and non-invasive prenatal testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA (cfDNA) testing market also includes sales of products such as digital PCR systems, automated nucleic acid extraction systems, real-time PCR instruments, and library preparation systems for NGS. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cell Free DNA (cfDNA) Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cell free dna (cfdna) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cell free dna (cfdna) testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell free dna (cfdna) testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product: Donor-Derived Cell-Free DNA; Circulating Cell-Free Tumor DNA; Cell-Free Fetal DNA
2) By Platforms: Next Generation Sequencing (NGS); rPCR And Multiplexed PCR; qPCR And dPCR; Other platforms
3) By Application: Oncology; Non-Invasive Prenatal Test (NIPT); Gynecology; Transplantation; Other Applications
Subsegments:
1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring; Graft Rejection Detection
2) By Circulating Cell-Free Tumor DNA: Cancer Detection; Minimal Residual Disease Monitoring; Liquid Biopsy
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Cell Free DNA (cfDNA) Testing Market Characteristics
3. Cell Free DNA (cfDNA) Testing Market Trends And Strategies
4. Cell Free DNA (cfDNA) Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Cell Free DNA (cfDNA) Testing Growth Analysis And Strategic Analysis Framework
5.1. Global Cell Free DNA (cfDNA) Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cell Free DNA (cfDNA) Testing Market Growth Rate Analysis
5.4. Global Cell Free DNA (cfDNA) Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cell Free DNA (cfDNA) Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cell Free DNA (cfDNA) Testing Total Addressable Market (TAM)
6. Cell Free DNA (cfDNA) Testing Market Segmentation
6.1. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Donor-Derived Cell-Free DNA
Circulating Cell-Free Tumor DNA
Cell-Free Fetal DNA
6.2. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Next Generation Sequencing (NGS)
rPCR and Multiplexed PCR
qPCR and dPCR
Other Platforms
6.3. Global Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Non-Invasive Prenatal Test (NIPT)
Gynecology
Transplantation
Other Applications
6.4. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Donor-Derived Cell-Free DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Organ Transplant Monitoring
Graft Rejection Detection
6.5. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Circulating Cell-Free Tumor DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Detection
Minimal Residual Disease Monitoring
Liquid Biopsy
6.6. Global Cell Free DNA (cfDNA) Testing Market, Sub-Segmentation Of Cell-Free Fetal DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Invasive Prenatal Testing (NIPT)
Fetal Genetic Disorder Screening
7. Cell Free DNA (cfDNA) Testing Market Regional And Country Analysis
7.1. Global Cell Free DNA (cfDNA) Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cell Free DNA (cfDNA) Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Cell Free DNA (cfDNA) Testing Market
8.1. Asia-Pacific Cell Free DNA (cfDNA) Testing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Cell Free DNA (cfDNA) Testing Market
9.1. China Cell Free DNA (cfDNA) Testing Market Overview
9.2. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Cell Free DNA (cfDNA) Testing Market
10.1. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Cell Free DNA (cfDNA) Testing Market
11.1. Japan Cell Free DNA (cfDNA) Testing Market Overview
11.2. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Cell Free DNA (cfDNA) Testing Market
12.1. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Cell Free DNA (cfDNA) Testing Market
13.1. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Cell Free DNA (cfDNA) Testing Market
14.1. South Korea Cell Free DNA (cfDNA) Testing Market Overview
14.2. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Cell Free DNA (cfDNA) Testing Market
15.1. Western Europe Cell Free DNA (cfDNA) Testing Market Overview
15.2. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Cell Free DNA (cfDNA) Testing Market
16.1. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Cell Free DNA (cfDNA) Testing Market
17.1. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Cell Free DNA (cfDNA) Testing Market
18.1. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Cell Free DNA (cfDNA) Testing Market
19.1. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Cell Free DNA (cfDNA) Testing Market
20.1. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Cell Free DNA (cfDNA) Testing Market
21.1. Eastern Europe Cell Free DNA (cfDNA) Testing Market Overview
21.2. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Cell Free DNA (cfDNA) Testing Market
22.1. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Cell Free DNA (cfDNA) Testing Market
23.1. North America Cell Free DNA (cfDNA) Testing Market Overview
23.2. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Cell Free DNA (cfDNA) Testing Market
24.1. USA Cell Free DNA (cfDNA) Testing Market Overview
24.2. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Cell Free DNA (cfDNA) Testing Market
25.1. Canada Cell Free DNA (cfDNA) Testing Market Overview
25.2. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Cell Free DNA (cfDNA) Testing Market
26.1. South America Cell Free DNA (cfDNA) Testing Market Overview
26.2. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Cell Free DNA (cfDNA) Testing Market
27.1. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Cell Free DNA (cfDNA) Testing Market
28.1. Middle East Cell Free DNA (cfDNA) Testing Market Overview
28.2. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Cell Free DNA (cfDNA) Testing Market
29.1. Africa Cell Free DNA (cfDNA) Testing Market Overview
29.2. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Platforms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Cell Free DNA (cfDNA) Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Cell Free DNA (cfDNA) Testing Market Competitive Landscape And Company Profiles
30.1. Cell Free DNA (cfDNA) Testing Market Competitive Landscape
30.2. Cell Free DNA (cfDNA) Testing Market Company Profiles
30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Cell Free DNA (cfDNA) Testing Market Other Major And Innovative Companies
31.1. Illumina Inc.
31.2. Qiagen N.V.
31.3. Exact Sciences Corporation
31.4. Bio-Techne Corporation
31.5. Natera Inc.
31.6. Myriad Genetics Inc.
31.7. NeoGenomics Laboratories Inc.
31.8. Invitae Corporation
31.9. Foundation Medicine Inc.
31.10. Guardant Health Inc.
31.11. Integrated DNA Technologies Inc.
31.12. Caris Life Sciences Inc.
31.13. Twist Bioscience Corporation
31.14. Adaptive Biotechnologies Corporation
31.15. Biodesix Inc.
32. Global Cell Free DNA (cfDNA) Testing Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Cell Free DNA (cfDNA) Testing Market
34. Recent Developments In The Cell Free DNA (cfDNA) Testing Market
35. Cell Free DNA (cfDNA) Testing Market High Potential Countries, Segments and Strategies
35.1 Cell Free DNA (cfDNA) Testing Market In 2029 - Countries Offering Most New Opportunities
35.2 Cell Free DNA (cfDNA) Testing Market In 2029 - Segments Offering Most New Opportunities
35.3 Cell Free DNA (cfDNA) Testing Market In 2029 - Growth Strategies
